Kumar Arvind, Porwal Mayur, Verma Ankita, Mishra Arun K
J Chemother. 2014 Dec;26(6):321-7. doi: 10.1179/1973947814Y.0000000201. Epub 2014 Jul 9.
Pomalidomide (Pomalyst(®)) is a synthetic compound derived by modifying the chemical structure of thalidomide to improve its potency and reduce its side effects and third drug in the class of immunomodulatory drugs. Pomalidomide is under global development with Celgene Corporation, was approved by the U.S. Food and Drug Administration on February 8, 2013 to treat patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior therapies including bortezomib and lenalidomide. In October 2009, it has found orphan designation for the treatment of relapsed and refractory MM by the EMA, and on August 2013, marketing authorization has issued in Europe by gaining a positive response. It inhibits myeloma cell growth and angiogenesis directly. Pomalidomide is the latest myeloma cell growth inhibitor to be approved in both USA and EU. The predominant side effects are thrombocytopenia, neuropathy, and deep vein thrombosis. Pomalidomide is also being investigated in patients with amyloidosis, prostate cancer, small cell lung cancer, pancreatic cancer, graft-versus-host disease, and Waldenstrom's macroglobulinemia. This article reviews the available information on pomalidomide with respect to its clinical pharmacology, mechanism of action, pharmacokinetics, pharmacodynamics, metabolism, pre-clinical studies, and clinical trials.
泊马度胺（Pomalyst(®)）是一种合成化合物，通过修饰沙利度胺的化学结构而衍生出来，以提高其效力并减少副作用，是免疫调节药物类中的第三种药物。泊马度胺正在与新基公司进行全球开发，于2013年2月8日获得美国食品药品监督管理局批准，用于治疗接受过至少两种包括硼替佐米和来那度胺在内的先前疗法的复发和难治性多发性骨髓瘤（MM）患者。2009年10月，它被欧洲药品管理局认定为治疗复发和难治性MM的孤儿药，2013年8月，在获得积极回应后在欧洲获得上市许可。它直接抑制骨髓瘤细胞生长和血管生成。泊马度胺是美国和欧盟批准的最新骨髓瘤细胞生长抑制剂。主要副作用是血小板减少、神经病变和深静脉血栓形成。泊马度胺也正在用于淀粉样变性、前列腺癌、小细胞肺癌、胰腺癌、移植物抗宿主病和华氏巨球蛋白血症患者的研究中。本文综述了有关泊马度胺的临床药理学、作用机制、药代动力学、药效学、代谢、临床前研究和临床试验的现有信息。
